Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
Nidhi Tandon, Vijay Ramakrishnan, Shaji K Kumar Division of Hematology, Mayo Clinic, Rochester, MN, USA Abstract: The incorporation of various novel therapies has resulted in a significant survival benefit in newly diagnosed and relapsed patients with multiple myeloma (MM) over the past decade. Des...
Guardado en:
Autores principales: | Tandon N, Ramakrishnan V, Kumar SK |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/26d3b8dbfff24a37b6b8c41b820ae08f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
por: Joseph NS, et al.
Publicado: (2021) -
The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani MS, et al.
Publicado: (2018) -
Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer
por: Bingyi Zhou, et al.
Publicado: (2021) -
GM101 in Combination with Histone Deacetylase Inhibitor Enhances Anti-Tumor Effects in Desmoplastic Microenvironment
por: Han-Gyu Chang, et al.
Publicado: (2021) -
A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma
por: Hao Wang, et al.
Publicado: (2021)